
A recent phase 3b clinical trial evaluated the efficacy and safety of esketamine nasal spray compared to extended-release quetiapine as augmentation therapy alongside selective serotonin reuptake inhibitors (SSRIs) or serotonin–norepinephrine reuptake inhibitors (SNRIs) in patients with treatment-resistant depression. The study, which was single-blind with raters unaware of group assignments, found that the esketamine group had a higher rate of remission at week 8 (27.1% vs 17.6% in the quetiapine group). Additionally, more esketamine-treated patients maintained remission without relapse through week 32. The findings suggest the potential superiority of esketamine nasal spray in treating treatment-resistant depression when combined with SSRIs or SNRIs.
Like
Save
Share